

*In addition to the panel members below, Touch Briefings would like to thank*

**Roger Brunkow** *President, Society of Bioprocessing Professionals, Sharon Grimster* *Chair of the Manufacturing Advisory Committee (MAC), Bioindustry Association (BIA), San King* *Director, Engineering Technology, Process R&D, Society of Biological Engineers, Sara Radcliffe* *Managing Director, Science and Regulatory Affairs, Biotechnology Industry Association (BIO), Dr Arne Staby* *Head of Protein Separation, Novo Nordisk, Professor Daniel I C Wang* *Chair of the Managing Board, Society of Biological Engineers (SBE)*

### **Dorothee Ambrosius**

*Director, Downstream Development, Boehringer Ingelheim*

Dorothee Ambrosius joined Boehringer Ingelheim in 2003. She currently heads the downstream development department at Boehringer Ingelheim in Biberach. The downstream department is responsible for the development of robust and economic purification processes for biopharmaceutical medicines derived from mammalian cell culture starting from bench scale up to 2000L GMP scale for generation of clinical grade material. Dr Ambrosius has a broad expertise in

biochemistry/protein chemistry and over 15 years of experience in identification and development of novel biopharmaceutical proteins (antibodies and proteins factors) from different sources. She completed her PhD in biology at the RWTH in Aachen and joint Boehringer-Mannheim, biotechnology Research Center in 1989. She held several research management positions at Boehringer-Mannheim and Roche in the area of recombinant protein production. ■

### **Tony Bradshaw**

*Director, BioProcess UK, BioIndustry Association (BIA)*

Tony Bradshaw joined the British BioIndustry Association (BIA) in 2004 and is currently Director of BioProcessUK. He earned his PhD in biochemistry from Heriot Watt University, Edinburgh, in 1988. He then worked as Biotechnology Business Development Advisor for British Sugar. In 1994 Dr Bradshaw

was Director of Business Development for University College London's Advanced Centre for Biochemical Engineering from where he moved to Ruston Poole and Harvey Nash to Executive Search in 1999 recruiting senior management for early stage bioscience companies. ■

### **John Dingerdisen**

*Vice President, Worldwide Manufacturing, Global Biologics Supply Chain LLC, Johnson & Johnson*

John Dingerdisen obtained his Masters of Science in Medicinal Chemistry from The School of Pharmacy, Purdue University in 1973. For several years he held the positions of increasing technical responsibility in Smith Kline and French Lab's Biopharmaceutical R&D Division. His team produced clinical supplies of antibiotics, r-DNA molecules including tPA and various vaccines. He has published extensively in the field of large-scale chromatography. He completed the Wharton Evening Management Program at the University of Pennsylvania

in 1985. After a period in R&D management he spent a few years as the head of DuPont's Medical Products Division r-DNA pilot plant in Glasgow, DE. In 1990, Mr Dingerdisen assumed responsibility for developing a Technical Services group within Merck's Vaccine Operations organisation. In 2001, Mr Dingerdisen assumed his present position at Centocor, responsible for Worldwide Manufacturing Operations including four plants and several contract manufacturing arrangements supplying ~US\$7.5 billion of biotech products. ■

### **Jeongbin Yim**

*Professor of Biological Sciences, Seoul National University (SNU) and Director, Korea Bio-MAX Center*

Jeongbin Yim is Professor of Biological Sciences at Seoul National University (SNU) and director of the Korea Bio-MAX Center, a newly established biotechnology research institute by SNU to promote pioneering and innovative research with a strong emphasis on interdisciplinary biotechnology areas. He also serves as president of Asia-Pacific International Molecular Biology Network (A-IMBN), dedicated to promoting molecular biology and biotechnology in the Asia-Pacific region. In 1999, Professor Yim served as president of the Microbiological Society

of Korea, in 2003, President of the Korean Society for Molecular and Cell Biology, and from 1993 to 1999, Director of the Institute of Molecular Biology and Genetics, SNU. Dr Yim received his PhD in biochemistry from Massachusetts Institute of Technology and received postdoctoral training at Oak Ridge National Laboratory where he later was appointed as a staff member. He has been well recognised for his scientific achievements of more than 120 scientific papers, numerous proceedings and patents. ■

**Thibaud Stoll***Head, Manufacturing Huningue, Novartis Pharma S.A.S*

Thibaud Stoll is Head of Bioprocessing at the new Novartis biotechnology manufacturing facility, located in Huningue, France. He is responsible for all the cell culture operations, from the seed lab to large-scale production in bioreactors (ca 14.5 m<sup>3</sup>). He has been a member of the start-up team of this facility from the beginning and, as such, has participated in or managed several activities such as equipment qualification (IQ, OQ, PQ), process transfer and validation, staffing and training of personnel. Dr Stoll started his professional activities at

Genentech, Inc., in cell culture R&D. He was then head of chemical production planning in a chemical plant of Firmenich SA (Switzerland), where he was in charge of planning and coordinating the fermentation and chemical production campaigns for fragrance and aroma compounds, including all the toll-manufacturing activities. Dr Stoll holds an MS in chemical engineering from MIT and a PhD in biochemical engineering from the Swiss Federal Institute of Technology (EPFL) in Lausanne, Switzerland ■

**Andreas Werner***Head, Biopharmaceutical Production Management, Boehringer Ingelheim*

Andreas Werner works for the Corporate Division Biopharmaceuticals of Boehringer Ingelheim GmbH and is responsible for the strategic production management of the Corporate Division Biopharmaceuticals. In his function he evaluates biopharmaceutical production technologies, allocates products to

production sites, optimises efficiency, creates investment strategies, engages outsourcing to strategic partners and monitors product life cycles. He has a biotechnology background and taught as an assistant professor at the University of Bielefeld, Germany, from 2001 to 2002 before joining Boehringer Ingelheim. ■

**Florian Wurm***President, European Society for Animal Cell Technology (ESACT)*

Florian Maria Wurm is Professor of Molecular and Cellular Biotechnology at the Swiss Federal Institute of Technology (EPFL) in Lausanne, Switzerland. As well as teaching responsibilities, Professor Wurm leads a research group of around 30 scientists and engineers. Professor Wurm is recognised internationally as one of the leading animal cell technologists with both industrial and academic backgrounds. He has been one of the pioneering scientists in establishing processes based on CHO cells and his research and development efforts have both pushed

forward the productivity of such processes and contributed to a better understanding of the genetics, physiology and process constraints of recombinant cells in large-scale manufacturing. His main scientific interest lies in the field of gene transfer to animal cells and he has published over 130 scientific papers. Professor Wurm has been the President of the European Society for Cell Technology (ESACT) since 2005. He is also the CSO, founder and member of the board of the start-up company ExcellGene, based in Monthey, Switzerland. ■

**Miranda Gek Sim Yap***Executive Director, Bioprocessing Technology Institute (BTI)*

Miranda Gek Sim Yap is Executive Director of the Bioprocessing Technology Institute, a national institute funded by the Agency for Science, Technology and Research in Singapore. Professor Yap is also Co-Chair of the Singapore-MIT

Alliance (SMA) Molecular Engineering of Biological and Chemical Systems programme. Professor Yap's research focus includes process development, modelling and optimisation of biological systems. ■

*The NanoBiotechnology Advisory Panel members are*

- Mansoor M Amiji** *Associate Professor, Department of Pharmaceutical Sciences School of Pharmacy Northeastern University*  
**Robert A Freitas Jr JD** *Senior Research Fellow, Institute for Molecular Manufacturing (IMM) (MAC), Bioindustry Association (BIA)*  
**Vincent Gau** *Chief Executive Officer and President, GeneFluidics*  
**Piotr Grodzinski** *Director, Nanotechnology for Cancer Programs, NCI Alliance for Nanotechnology in Cancer*  
**Kolb** *President, Society for Biomolecular Screening (SBS)*  
**Luke Lee** *Director, UC Berkeley Biomolecular Nanotechnology Center*  
**Chih-Ming R Ho** *Professor, Mechanical and Aerospace Engineering and Member, Brain Research Institute, California Nanosystems Institute*  
**Hayat Onyuksel** *Professor and Associate Head, Department of Biopharmaceutical Sciences University of Illinois at Chicago*  
**Gabriel A Silva** *Assistant Professor, Departments of Bioengineering and Ophthalmology, and Neurosciences Program University of California, San Diego*